Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Vanuatu Health Times.
Press releases published on September 12, 2025
ProText Mobility, Inc. Provides Shareholder Update
WILMINGTON, Del., Sept. 12, 2025 (GLOBE NEWSWIRE) -- ProText Mobility, Inc. (OTC: TXTM), is delighted to announce that the OTC Markets Group (OTCM) informed the company that the “caveat emptor” designation has been removed and the company is current in its …
Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc., (Nasdaq: COCP) (the “Company” or …
Vystar® to restart sales of Vytex® Cloud Bed-in-a-Box
Luxuriously soft supportive comfort, resilience and breathability Thicker mattress and the ultimate plush covering 6 sizes, 3 levels of softness World’s purest, naturally anti-microbial, odor-free and virtually allergen free latex Made of globally patented …
Intuitive Introduces Real-Time Surgical Insights for da Vinci 5
SUNNYVALE, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the first in a series of new software capabilities for da …
American Kidney Fund Convenes Kidney Community Members for Sixth Annual Summit on Unknown Causes of Kidney Disease
ROCKVILLE, Md., Sept. 12, 2025 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF)'s sixth annual national summit on Unknown Causes of Kidney Disease (UCKD) will focus in part on rural and community outreach and multidisciplinary health care for kidney …
Olympia Pharmaceuticals Wins Orlando Business Journal’s Family-Owned Business Award
The state-of-the-art 503B pharmaceutical outsourcing facility and 503A pharmacy has been recognized in the Expansion category for its family legacy amid astonishing growth ORLANDO, Fla., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Olympia Pharmaceuticals – a state- …
HealthLynked Strengthens Intellectual Property Portfolio with New Patent Filings in AI and Patient Record Management
NAPLES, Fla., Sept. 12, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB: HLYK), a leader in patient-centric healthcare technology, today announced the submission of two new U.S. patent applications, further expanding the company's …
24/7 Market News: Kraig Labs Positioned at the Forefront of the Next-Gen Materials Revolution
DENVER, Sept. 12, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, reminds interested parties that Kraig Biocraft Laboratories (OTCQB: KBLB), the undisputed …
Interim results for the six months ended June 30, 2025
September 12, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative …
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company’s Board of Directors and will step down from the Board to join ALX as Interim Chief Medical Officer …
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the “Company”), today announced that it has received a written notice ( …
Prenetics Announces Second Quarter 2025 Financial Results with IM8 on Track to Achieve $100M Annual Recurring Revenue by Year’s End
1st Half revenue grew 452.1% to $32.3 million YoY IM8 achieved $5.9 million revenue in August 2025, representing a CAGR1 of over 3,100% Prenetics increases FY2025 revenue guidance range of $85 – $100 million Prenetics provides update on Bitcoin Treasury, …
FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies
HOUSTON, Sept. 12, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic …
Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference
BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-CEO Sam Lee, PhD discussed the scientific foundation and clinical progress with the Company’s lead pan-viral protease inhibitor CDI-988 …
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for …
ProPhase Labs Stockholders Approve All Proposals at September 9, 2025 Special Meeting By More Than 75% In Favor
ProPhase Labs Stockholders Deliver Strong Mandate at Special Meeting UNIONDALE, NY, Sept. 12, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics and consumer products company, …
Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease
Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug Designation in the U.S., Europe, and Japan; and Pioneer Drug Designation in Japan for Stargardt disease Last subject visit …
Gelteq Technology Powers U.S. Product Launches of its Nutraceutical Products for Partner
MELBOURNE, Australia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company,” NASDAQ: GELS), a clinical and science-based developer of gel-based oral delivery solutions, welcomes the recently announced product launches of Healthy …
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
Ra’anana, Israel, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced encouraging preclinical results supporting the …
Progress in clinical development for Alzheimer’s and other indications: Galimedix Therapeutics successfully completes Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator
GAL-101 was well tolerated; excellent safety and pharmacokinetic profile strongly support oral administration GAL-101 effectively crosses the blood-brain barrier, supporting further development in Alzheimer’s disease A Phase 2 trial in Alzheimer’s disease …